Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative malignancy with an estimated incidence in the world of 1-2 cases per 100,000 adults. The use of Tyrosine Kinase Inhibitors (TKI) as a therapy for CML is still the first choice for treatment, but some cases show a high level of resistance or intolerance to TKI therapy. This study aims to identify the therapeutic responses of imatinib and nilotinib among CML patients in Bandung.Method: This study is an analytical descriptive study of CML patients at Hasan Sadikin Hospital’s Hematology and Medical Oncology Outpatient Clinic in 2017. The total number of samples in this study is 244 patients, consisting of 199 patients with Imatinib therapy and 45 patients with Nilotinib therapy. The data is processed using SPSS Statistics 22.0 software.Result: The results showed that CML patients had a median age of 42 years, sex ratio of 1: 1 and the highest prevalence was in Bandung City (21.3%). Hematologic response is dominated by complete hematologic response, as high as 72.86% with Imatinib and 66.67% with Nilotinib. Molecular response 3-6 months post therapy is dominated by suboptimal response in as many as 36,8% with Imatinib and failure in as many as 50% with Nilotinib. Molecular response 12-18 months post therapy is dominated by failure in as high as 69,4% with Imatinib and 52,4% with Nilotinib.Conclusion: Based on the molecular response, the rates of suboptimal response and resistance are quite high. Regular monitoring standards of therapy for CML patients are needed to identify TKI resistance so alternative therapies can be provided to improve the outcomes.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Background: Langerhans Cell Histiocytosis (LCH) is a disease characterized by proliferation and infiltration of histiocytes in various organs that is caused by local or systemic effects. LCH could affect bones, lungs, central nervous system, liver, thymus, skin, and lymph nodes. The diagnosis of LCH is difficult to enforce and rarely found in adults, namely 1-2 cases per million per year.Case Presentation: In Indonesia, there were very few cases of LCH in adults, one of which was found in women aged 56 years. LCH does not yet have standard treatments. The treatment is given based on location and severity, including intralesional corticosteroid injection, radiotherapy, surgical or excision curettage, and chemotherapy. Prednisone and vinblastine chemotherapy was one of chemotherapy that is given to LCH patients. Prognosis of LCH consists of various factors, one of which is the number of organs involved. This is a case report of LCH in an adult male patient with skin involvement who received chemotherapy for 6 weeks and experienced improvement.Conclusions: LCH is not only a disease of children; it is also reported in an adult. The prognosis is related to the number of organ involved and involvement of the risk organ. LCH can recur easily and accompany malignant tumors, so follow-up and long-term observations are still needed to be done.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.